An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetacoplan in the Treatment of Post-Transplant Recurrence of C3G or IC-MPGN
Latest Information Update: 27 May 2024
At a glance
- Drugs Pegcetacoplan (Primary)
- Indications Membranoproliferative glomerulonephritis
- Focus Therapeutic Use
- Acronyms NOBLE
- Sponsors Apellis Pharmaceuticals
- 24 May 2024 According to an Apellis Pharmaceuticals Media Release, data from this study were presented at the European Renal Association (ERA) Congress taking place May 23-26 in Stockholm, Sweden.
- 24 May 2024 Positive 1-year Results presented in an Apellis Pharmaceuticals Media Release.
- 05 Mar 2024 Planned End Date changed from 1 Nov 2023 to 1 Jan 2026.